Abp 234 vs Camrelizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Abp 234
Developed by Amgen
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06430866 (registry estimate)
No aligned efficacy figure on record for this race.
Camrelizumab
Marketed by Jiangsu Hengrui Pharmaceuticals and partners
NCT03134872 · Phase 3 · completed
CameL was a randomized, open-label Phase 3 trial in 419 patients with untreated non-squamous non-small-cell lung cancer without EGFR or ALK alterations, which compared camrelizumab plus carboplatin and pemetrexed with chemotherapy alone. It had two primary endpoints: progression-free survival in all patients and in PD-L1-positive patients. At the interim analysis, progression-free survival in all patients was significantly longer with camrelizumab (11.3 vs 8.3 months; hazard ratio 0.60). The paper reports confirmatory testing only for all patients, and no published result tests the PD-L1-positive primary, so the result is shown as unclear. The figures come from the peer-reviewed paper (Zhou et al., Lancet Respir Med 2021).
Next expected readout: December 2027 · NCT07016126 (registry estimate)
Reported efficacy
Progression-Free Survival in the intent-to-treat (ITT) population (up to 24 months); Progression-Free Survival in the PD-L1-selected population (up to 24 months): Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported. (unclear)
Result source: NCT03134872
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Abp 234 | Camrelizumab |
|---|---|---|
| PFS, median | —Trial running · NCT06430866 | 11.3 vs 8.3avs carboplatin + pemetrexed alone, PCNCT03134872 |
| OS, median | —Trial running · NCT06430866 | —Not posted · NCT03134872 |
| ORR | —Trial running · NCT06430866 | 16.7%bNCT03083041 |
| Duration of response, median | —Trial running · NCT06430866 | —Not posted · NCT03134872 |
PFS, median
- Abp 234
- —Trial running · NCT06430866
- Camrelizumab
- 11.3 vs 8.3avs carboplatin + pemetrexed alone, PCNCT03134872
OS, median
- Abp 234
- —Trial running · NCT06430866
- Camrelizumab
- —Not posted · NCT03134872
ORR
- Abp 234
- —Trial running · NCT06430866
- Camrelizumab
- 16.7%bNCT03083041
Duration of response, median
- Abp 234
- —Trial running · NCT06430866
- Camrelizumab
- —Not posted · NCT03134872
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Abp 234: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Abp 234: 0 of 4 rows · Camrelizumab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Camrelizumab |
|---|---|
| Dropout rate | 91.7%375 mga NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result—250 mg NCT03083041 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —375 mga NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result—250 mg NCT03083041 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 58.3%375 mga NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result56.6%250 mg NCT03083041 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 375 mga rash 91.7% hypertension 83.3% decreased appetite 75% NCT03083041 · Phase 2 · registry result, not featured evidence · combination show 1 more result250 mg hypertension 63.6% proteinuria 63.1% aspartate aminotransferase increased 53.5% NCT03083041 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Camrelizumab
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abp 234's landscape · Camrelizumab's landscape